A preclinical/clinical phase II study demonstrated that targeting the canonical NF-κB pathway through inhibition of the 26S proteasome complex with bortezomib can selectively sensitize patients with relapsed/refractory ABC-DLBCL, but not patients with relapsed/refractory GCB-DLBCL, to chemotherapy (including (R-)CHOP and DA-EPOCH) [263]. Here, NFKB1 is linked to aneurysmal bone cyst.